Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Exercise during chemotherapy supports physical and cognitive health

13

Mar 2026

Exercise during chemotherapy supports physical and cognitive health

​Researchers recommended a tailored, scientifically validated exercise program to individuals receiving chemotherapy for cancer, and those who were on a two-week chemotherapy schedule and followed the exercise prescription were able to maintain their walking-step goals, use resistance bands, and stay mentally sharper compared to patients who did not exercise.

Early prenatal shunt treatment improves outcomes for fetal megacystis

13

Mar 2026

Early prenatal shunt treatment improves outcomes for fetal megacystis

An interdisciplinary team from the University Hospitals Cologne and Bonn have conducted the first prospective study to investigate whether very early intervention in unborn children with congenital lower urinary tract obstruction (cLUTO) can improve their chances of survival and subsequent kidney function.

Updated EULAR recommendations guide treatment decisions for rheumatoid arthritis

13

Mar 2026

Updated EULAR recommendations guide treatment decisions for rheumatoid arthritis

First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease, have been relied upon by healthcare professionals and organisations worldwide to offer an up-to-date and robust analysis of the effectiveness and practical use of available DMARDs – from conventional agents such as methotrexate to biologics and Janus kinase (JAK) inhibitors.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.